Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.

Read the full Articles here:

thelancet.com/journals/lanonc/article/PIIS1470…)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

thelancet.com/journals/lanonc/article/PIIS1470…)00503-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode (buzzsprout.com/1391338/fan_mail/new)

Continue this conversation on social!

Follow us today at...

thelancet.bsky.social

instagram.com/thelancetgroup

facebook.com/thelancetmedicaljournal

linkedIn.com/company/the-lancet (linkedin.com/company/the-lancet)

youtube.com/thelancettv